Charles River Laboratories International, Inc.(CRL) Stock Research - Grey Stern Research

Charles River Laboratories International, Inc. (CRL) Stock Analysis

$233.47 (5.26%)

CRL Financial Performance


Use the table below to view Charles River Laboratories International, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q1 - 2024

Metric Value Ranking among Peers
Price $221.81 -
52 Week Low $161.65 -
52 Week High $275.00 -
Market Cap $11.4 Billion 10/14
Gross Margin 32% 8/14
Profit Margin 7% 8/14
EBITDA margin 23% 5/14
Q1 - 2024 Revenue $1.0 Billion 7/14
Q1 - 2024 Earnings $67.3 Million 9/14
Q1 - 2024 Free Cash Flow $50.7 Million 8/14
Trailing 4 Quarters Revenue $4.1 Billion 7/14
Trailing 4 Quarters Earnings $438.8 Million 8/14
Quarterly Earnings Growth -35% 11/14
Annual Earnings Growth -34% 10/14
Quarterly Revenue Growth -2% 9/14
Annual Revenue Growth -5% 8/14
Cash On Hand $337.4 Million 8/14
Short Term Debt $2.6 Million 14/14
Long Term Debt $2.6 Billion 5/14

Charles River Laboratories International, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Charles River Laboratories International, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 26.04 10/14
PS 2.78 11/14
PB 3.08 9/14
PC 33.87 7/14
Liabilities to Equity 1.22 6/14
ROA 0.05 6/14
ROE 0.12 7/14
Current Ratio 1.83 7/14
Quick Ratio 0.08 9/14
Long Term Debt to Equity 0.72 5/14
Debt to Equity 0.85 4/14
Burn Rate 8.73 1/14
Cash to Cap 0.03 6/14
CCR 0.75 7/14
EV to EBITDA 62.06 10/14
EV to Revenue 3.45 10/14

Company Details

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

CEO: Mr. James Foster

Website: https://www.criver.com

Address: 251 Ballardvale St Wilmington, MASSACHUSETTS

Exchange: New York Stock Exchange

Industry: Diagnostics & Research

Charles River Laboratories International, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Charles River Laboratories International, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
CareDx, Inc CDNA $990.1 Million
Syneos Health, Inc. SYNH $4.5 Billion
Agilent Technologies, Inc. A $40.1 Billion
Illumina, Inc. ILMN $19.2 Billion
Laboratory Corporation of America Holdings LH $17.8 Billion
IDEXX Laboratories, Inc. IDXX $38.8 Billion
IQVIA Holdings Inc. IQV $43.7 Billion
Waters Corporation WAT $18.9 Billion
Mettler-Toledo International Inc. MTD $31.0 Billion
ICON Public Limited Company ICLR $26.7 Billion
Invitae Corporation NVTA $5.4 Million
Medpace Holdings, Inc. MEDP $11.8 Billion
Guardant Health, Inc. GH $4.0 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
CRL Income Statements
Quarter Year Revenue Earnings
Q1 2024 $ 1.0 Billion $67.3 Million
Q4 2023 $ 1.0 Billion $187.1 Million
Q3 2023 $ 1.0 Billion $87.4 Million
Q2 2023 $ 1.1 Billion $97.0 Million
Q1 2023 $ 1.0 Billion $103.1 Million
Q4 2022 $ 1.1 Billion $187.4 Million
Q3 2022 $ 989.2 Million $96.5 Million
Q2 2022 $ 973.1 Million $109.3 Million

View All

CRL Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q1 2024 $337.4 Million $8.2 Billion $3.1 Billion $3.7 Billion
Q4 2023 $276.8 Million $8.2 Billion $3.1 Billion $3.7 Billion
Q3 2023 $157.2 Million $7.6 Billion $2.9 Billion $3.4 Billion
Q2 2023 $200.4 Million $7.8 Billion $3.1 Billion $3.3 Billion
Q1 2023 $201.6 Million $7.7 Billion $3.2 Billion $3.1 Billion
Q4 2022 $233.9 Million $7.6 Billion $3.1 Billion $3.0 Billion
Q3 2022 $193.7 Million $7.4 Billion $3.3 Billion $2.7 Billion
Q2 2022 $200.3 Million $7.5 Billion $3.4 Billion $2.7 Billion

View All

CRL Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q1 2024 $50.7 Million -$79.1 Million $54.8 Million
Q4 2023 $142.6 Million -$78.3 Million $118.9 Million
Q3 2023 $139.5 Million -$65.9 Million -$43.2 Million
Q2 2023 $80.7 Million -$67.4 Million -$114,000
Q1 2023 $2.5 Million -$106.9 Million -$32.3 Million
Q4 2022 $145.7 Million -$89.0 Million $45.0 Million
Q3 2022 $60.4 Million -$72.4 Million -$11.0 Million
Q2 2022 $66.6 Million -$82.9 Million -$36.2 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions